ClinicalTrials.gg
CompletedNCT01313507NGAM-05Updated Mar 29, 2017Results posted

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

A Phase 3 interventional study of NewGam in Primary Immunodeficiency Disease, sponsored by Octapharma. Completed at 6 sites in United States. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Octapharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
2 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
23rd of 26
21 · median 45
Started
2011
with 6 others
Phase 3
18 of 27
2 open now
Registered
11th of 27
by date
Lead sponsor
3 of 27
Octapharma

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 23rd largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2011, is one of 18 in phase 3, and was the 11th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

This was a prospective, open-label, non-controlled, non-randomized multicenter Phase III study of 2 multiple-dose intravenous NewGam regimens (every 3 weeks or every 4 weeks, continuing the patient's infusion interval in the main study NCT01012323 [NGAM-01]) for 3 months. The primary objective of the study was to assess the safety and tolerability of high infusion rates of NewGam.

Read the detailed description

Patients received NewGam via an infusion pump to control precise infusion rates. All NewGam infusions started at a rate of 0.01 mL/kg/min (60 mg/kg/h) for the first 30 minutes followed by 0.03 mL/kg/min (180 mg/kg/h) for the next 15 minutes. If tolerated, further increments were made at predefined patterns with the following maximum rates: 0.10 mL/kg/min (600 mg/kg/h) in the first infusion; if this was tolerated, 0.12 mL/kg/min (720 mg/kg/h) in the second infusion; if this was tolerated, 0.14 mL/kg/min (840 mg/kg/h) in all subsequent infusions.

If an adverse event occurred during an infusion, the rate was reduced to half the rate at which the event occurred or the infusion was interrupted until symptoms subsided. The infusion was then resumed at a rate tolerated by the patient.

03

Conditions studied

  • Primary Immunodeficiency Disease

Keywords

  • Primary Immunodeficiency Disease
  • PID
04

Who can participate

Ages eligible
2 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of the main study NGAM-01.
  • At each of the last 3 infusions in the main study NGAM-01, administration of NewGam at the maximum infusion rate of 0.08 mL/kg/min and without the need for premedication.

Exclusion criteria

Exclusion Criteria:

  • Any condition or circumstance that would have led to the exclusion of the subject from the NGAM-01 study.
  • Administration of any immunoglobulin infusion other than NewGam between conclusion of the NGAM-01 study and the beginning of the present study.
  • A deviation of the subject's treatment interval of more than 7 days between the last infusion of NewGam in the NGAM-01 study and the first infusion of NewGam in the present study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    NewGam

    Participants received NewGam 200-800 mg/kg intravenously every 3 or 4 weeks for 3 months (5 or 4 total infusions, respectively).

    Biological: NewGam

Interventions

  • BiologicalNewGam

    The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced at Least 1 Adverse Event Causally Related to the Administration of the Study Drug

    An adverse event was considered to be causally related to the administration of the study drug if it judged to be probably or possibly related to the study drug, as assessed by the investigator.

    Time frame: Baseline (follow-up visit of study NGAM-01) to the end of the study (follow-up visit of study NGAM-05) (up to 4 months)

  2. Percentage of Participants Who Experienced at Least 1 Adverse Event Temporally Related to the Study Drug

    An adverse event was considered to be temporally related to the study drug if it started during an infusion or within 72 hours after the end of an infusion.

    Time frame: Baseline (follow-up visit of study NGAM-01) to the end of the study (follow-up visit of study NGAM-05) (up to 4 months)

Secondary outcomes

  1. Change From Baseline in the Quality of Life (QoL) at the End of the Study

    QoL was assessed with the Child Health Questionnaire-Parent Form (CHQ-PF50), completed by a parent or guardian, in participants \< 14 years of age at the start of the previous study NGAM-01 and with the Short Form-36 Health Survey (SF-36-HS) in participants ≥ 14 years of age. The CHQ-PF50 consists of 50 items organized into 15 subscales.The 15 subscales could be combined into 2 summary scores, physical and psychosocial. The calculated scores were transformed so that each scale had a range of 0-100. A higher score indicates better health. The SF-36-HS is composed of 36 items. Responses to the 36 items were combined to create 8 scales. The 8 scales could be further combined into 2 scores: Physical component summary and mental component summary. The item and scale scores were transformed to a range of 0-100 with a mean of 50 and a standard deviation of 10 in the general US population. A higher score indicates better health. For both instruments, a positive change indicates improvement.

    Time frame: Baseline (follow-up visit of study NGAM-01) to the end of the study (follow-up visit of study NGAM-05) (up to 4 months)

07

Results

Posted Mar 29, 2017

Participant flow

Participant flow — Overall Study
MilestoneNewGam
Started21
Completed21
Not completed0

Outcome measures

SecondaryChange From Baseline in the Quality of Life (QoL) at the End of the Study

QoL was assessed with the Child Health Questionnaire-Parent Form (CHQ-PF50), completed by a parent or guardian, in participants \< 14 years of age at the start of the previous study NGAM-01 and with the Short Form-36 Health Survey (SF-36-HS) in participants ≥ 14 years of age. The CHQ-PF50 consists of 50 items organized into 15 subscales.The 15 subscales could be combined into 2 summary scores, physical and psychosocial. The calculated scores were transformed so that each scale had a range of 0-100. A higher score indicates better health. The SF-36-HS is composed of 36 items. Responses to the 36 items were combined to create 8 scales. The 8 scales could be further combined into 2 scores: Physical component summary and mental component summary. The item and scale scores were transformed to a range of 0-100 with a mean of 50 and a standard deviation of 10 in the general US population. A higher score indicates better health. For both instruments, a positive change indicates improvement.

Time frame:
Baseline (follow-up visit of study NGAM-01) to the end of the study (follow-up visit of study NGAM-05) (up to 4 months)
Reported as:
Mean · Units on a scale
Change From Baseline in the Quality of Life (QoL) at the End of the Study
Units on a scaleNewGam
CHQ-PF50 - Physical component summary-2.63 ± 5.22
CHQ-PF50 - Psychosocial component summary-2.01 ± 5.78
SF-36 - Physical component summary0.21 ± 6.00
SF-36 - Mental component summary0.36 ± 7.33
PrimaryPercentage of Participants Who Experienced at Least 1 Adverse Event Causally Related to the Administration of the Study Drug

An adverse event was considered to be causally related to the administration of the study drug if it judged to be probably or possibly related to the study drug, as assessed by the investigator.

Time frame:
Baseline (follow-up visit of study NGAM-01) to the end of the study (follow-up visit of study NGAM-05) (up to 4 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced at Least 1 Adverse Event Causally Related to the Administration of the Study Drug
Percentage of participantsNewGam
Percentage of Participants Who Experienced at Least 1 Adverse Event Causally Related to the Administration of the Study Drug19.0
PrimaryPercentage of Participants Who Experienced at Least 1 Adverse Event Temporally Related to the Study Drug

An adverse event was considered to be temporally related to the study drug if it started during an infusion or within 72 hours after the end of an infusion.

Time frame:
Baseline (follow-up visit of study NGAM-01) to the end of the study (follow-up visit of study NGAM-05) (up to 4 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced at Least 1 Adverse Event Temporally Related to the Study Drug
Percentage of participantsNewGam
Percentage of Participants Who Experienced at Least 1 Adverse Event Temporally Related to the Study Drug38.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NewGam—0/21 (0%)12/21 (57.1%)
Most frequent other events
Most frequent other events
EventNewGam
SinusitisInfections and infestations4/21
NauseaGastrointestinal disorders3/21
VomitingGastrointestinal disorders3/21
Abdominal painGastrointestinal disorders2/21
DiarrhoeaGastrointestinal disorders2/21
Chest painGeneral disorders2/21
PyrexiaGeneral disorders2/21
HeadacheNervous system disorders2/21
NasopharyngitisInfections and infestations2/21
ContusionInjury, poisoning and procedural complications2/21

Baseline characteristics

Safety analysis set: All participants who received at least 1 dose of NewGam.

Age, Continuous
Age, Continuous(Years)NewGam
Mean23.8 ± 19.78
Sex: Female, Male
Sex: Female, Male(Participants)NewGam
Female8
Male13
08

Study locations

6 sites
  • University of California Irvine
    Irvine, California, United States
  • Immunoe Research Center
    Centennial, Colorado, United States
  • Rush Universtity Medical Center
    Chicago, Illinois, United States
  • Cardinal Glennon Children's Hospital
    St. Louis, Missouri, United States
  • Midlands Pediatrics
    Papillion, Nebraska, United States
  • Seattle Children's Hospital
    Seattle, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2011
First posted
Mar 11, 2011
Start
May 2011
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Mar 29, 2017
Last update
Mar 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01313507
Lead sponsor
Octapharma
Responsible party
Sponsor
First posted
Mar 11, 2011
Start date
May 2011
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Mar 29, 2017
Last update
Mar 29, 2017

Study contacts

James N Moy, MD
principal investigator · Rush Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion